Rational Drug Therapy of Peptic Ulcer Disease In Patients Admitted To Gastroenterology Ward of LRH Peshawar, Khyber Pakhtunkhwa, Pakistan
Keywords:PEPTIC ULCER DISEASE, infection Rate, drug therapy
The present study was conducted from 12 Sep.2019 to 10 Nov. 2019 at the Gastroenterology ward, Lady Reading Hospital Peshawar Pakistan, aiming to accurately investigate the Peptic Ulcer Disease state, signs and symptoms, to ensure complete information about drug therapy and patients response. Peptic ulcer disease is defined as an upper gastric mucosal rupture due to acid hat results in the formation of ulcers that extend beyond the muscular mucosa to the submucosa. Peptic ulcer is characterized by abdominal pain, change in appetite, unexplained weight loss, nausea, vomiting, heart burn and dark, tarry stools. Spicy and acidic foods, Stress and restless lifestyle were considered to be the leading causes of peptic ulcer. However the Helicobacter pyloribacterium is responsible for up to 60% stomach ulcers. Frequent use of painkillers, old age, obesity Smoking, excessive alcohol use, too little sleep, type O blood and chronic stress, are the risk factors of peptic ulcers. Acute peptic ulcers results from taking aspirin or anti-inflammatory drugs. Chronic peptic ulcer represents a profound loss of substance. Data from a total of10 patients (6 female and 4 male)of all age, having various peptic ulcer diseases were involved in this study. It was concluded that most of the female patients (60%) were having peptic ulcers as compared to male patient (40%). It was found that 30-40 years old peptic ulcer patient percentage was 20%.Moreover it was observed that frequent use of Nonsteroidal Anti-inflammatory Drugs has been found to be the main causes of peptic ulcers
Lee, Y.Y., S. Mahendra Raj, and D.Y. Graham, Helicobacter pylori infection-a boon or a bane: lessons from studies in a low‐prevalence population. Helicobacter, 2013. 18(5): p. 338-346. doi: 10.1111/hel.12058.
Bertleff, M.J., et al., Randomized clinical trial of laparoscopic versus open repair of the perforated peptic ulcer: the LAMA Trial. World journal of surgery, 2009. 33(7): p. 1368-1373. doi: 10.1007/s00268-009-0054-y.
Ali, M., et al., Soil and water conservation practices in district Swabi, KP, Pakistan. Adv Crop Sci Tech, 2018. 6(366): p. 2. doi: 10.4172/2329-8863.1000366
Taha, A.S., et al., Famotidine for the prevention of peptic ulcers and oesophagitis in patients taking low-dose aspirin (FAMOUS): a phase III, randomised, double-blind, placebo-controlled trial. The Lancet, 2009. 374 (9684): p. 119-125. doi: 10.1016/S0140-6736(09)61246-0.
Cichoke, A.J., The complete book of enzyme therapy. A Complete and Up-To-Date Reference to Effective Remedies. 1999: Penguin.
Avery, A.J., et al., A pharmacist-led information technology intervention for medication errors (PINCER): a multicentre, cluster randomised, controlled trial and cost-effectiveness analysis. The Lancet, 2012. 379(9823): p. 1310-1319. doi:https://doi.org/10.1016/S0140-6736(11)61817-5
Sung, J., E. Kuipers, and H. El‐Serag, Systematic review: the global incidence and prevalence of peptic ulcer disease. Alimentary pharmacology & therapeutics, 2009. 29(9): p. 938-946. DOI: 10.1111/j.1365-2036.2009.03960.x
Wang, C.-H., et al., High-dose vs non-high-dose proton pump inhibitors after endoscopic treatment in patients with bleeding peptic ulcer: a systematic review and meta-analysis of randomized controlled trials. Archives of internal medicine, 2010. 170(9): p. 751-758. doi: 10.1001/archinternmed.2010.100.
Israel, D.A., et al., Helicobacter pylori strain-specific differences in genetic content, identified by microarray, influence host inflammatory responses. The Journal of clinical investigation, 2001. 107(5): p. 611-620. doi: 10.1172/JCI11450.
Schaffer, D., et al., Risk of serious NSAID‐related gastrointestinal events during long‐term exposure: a systematic review. Medical journal of Australia, 2006. 185(9): p. 501-506. doi:10.5694/j.1326-5377.2006.tb00665.x.
Roderick, P., et al., Cost-effectiveness of population screening for Helicobacter pylori in preventing gastric cancer and peptic ulcer disease, using simulation. Journal of Medical Screening, 2003. 10(3): p. 148-156. doi: 10.1177/096914130301000310.
Kahi, C.J., et al., Endoscopic therapy versus medical therapy for bleeding peptic ulcer with adherent clot: a meta-analysis. Gastroenterology, 2005. 129(3): p. 855-862. doi: 10.1053/j.gastro.2005.06.070.
Ng, F.H., et al., Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions. Gastroenterology, 2010. 138(1): p. 82-88. doi: 10.1053/j.gastro.2009.09.063.
Fallah, M.S., F. Mansour-Ghanaei, and A. Shafaghi, Eradication of Helicobacter pylori in duodenal ulcer disease tetracycline & furazolidone vs. metronidazole & amoxicillin in omeprazole based triple therapy. Medical Science Monitor, 2002. 8(3): p. PI27-PI30.
Lanza, F.L., A guideline for the treatment and prevention of NSAID-induced ulcers. The American journal of gastroenterology, 1998. 93(11): p. 2037. doi: 10.1111/j.1572-0241.1998.00588.x.
Graham, D., et al., Campylobacter pylori detected noninvasively by the 13C-urea breath test. The Lancet, 1987. 329(8543): p. 1174-1177. doi: 10.1016/s0140-6736(87)92145-3.
Yuan, Y., I.T. Padol, and R.H. Hunt, Peptic ulcer disease today. Nature Clinical Practice Gastroenterology & Hepatology, 2006. 3(2): p. 80-89. doi: 10.1038/ncpgasthep0393.
Genovese, M.C., et al., Interleukin‐6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease‐modifying antirheumatic drugs: the tocilizumab in combination with traditional disease‐modifying antirheumatic drug therapy study. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology, 2008. 58(10): p. 2968-2980. doi: 10.1002/art.23940.
Jain, S., M. Umesh, and H. Nandeesh, A study on prescription pattern of drugs used in the treatment of peptic ulcer disease in a tertiary care hospital.
Singh, G. and G. Triadafilopoulos, Appropriate choice of proton pump inhibitor therapy in the prevention and management of NSAID‐related gastrointestinal damage. International journal of clinical practice, 2005. 59(10): p. 1210-1217. doi: 10.1111/j.1368-5031.2005.00660.x.
How to Cite
Copyright (c) 2021 Pakistan BioMedical Journal
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open-access journal and all the published articles / items are distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. For comments firstname.lastname@example.org